RU2604813C2 - Функциональные растворимые гетеродимеры мнс ii класса со стабилизирующей дисульфидной связью - Google Patents

Функциональные растворимые гетеродимеры мнс ii класса со стабилизирующей дисульфидной связью Download PDF

Info

Publication number
RU2604813C2
RU2604813C2 RU2012138302/10A RU2012138302A RU2604813C2 RU 2604813 C2 RU2604813 C2 RU 2604813C2 RU 2012138302/10 A RU2012138302/10 A RU 2012138302/10A RU 2012138302 A RU2012138302 A RU 2012138302A RU 2604813 C2 RU2604813 C2 RU 2604813C2
Authority
RU
Russia
Prior art keywords
mhc class
molecule
domain
chain
recombinant
Prior art date
Application number
RU2012138302/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2012138302A (ru
Inventor
Гейр Оге ЛЁСЕТ
Терье ФРИГСТАД
Ингер САНДЛЬЕ
Бьярне БОГЕН
Original Assignee
Университетет И Осло
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Университетет И Осло filed Critical Университетет И Осло
Publication of RU2012138302A publication Critical patent/RU2012138302A/ru
Application granted granted Critical
Publication of RU2604813C2 publication Critical patent/RU2604813C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
RU2012138302/10A 2010-02-18 2011-02-18 Функциональные растворимые гетеродимеры мнс ii класса со стабилизирующей дисульфидной связью RU2604813C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US30572810P 2010-02-18 2010-02-18
GB1002730.8 2010-02-18
GBGB1002730.8A GB201002730D0 (en) 2010-02-18 2010-02-18 Product
US61/305,728 2010-02-18
US31657610P 2010-03-23 2010-03-23
US61/316,576 2010-03-23
PCT/GB2011/050325 WO2011101681A2 (en) 2010-02-18 2011-02-18 Disulphide bond-stabilized functional soluble mhc class ii heterodimers

Publications (2)

Publication Number Publication Date
RU2012138302A RU2012138302A (ru) 2014-03-27
RU2604813C2 true RU2604813C2 (ru) 2016-12-10

Family

ID=42113985

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012138302/10A RU2604813C2 (ru) 2010-02-18 2011-02-18 Функциональные растворимые гетеродимеры мнс ii класса со стабилизирующей дисульфидной связью

Country Status (18)

Country Link
US (2) US8828379B2 (https=)
EP (1) EP2536746B1 (https=)
JP (1) JP5537675B2 (https=)
KR (1) KR101647176B1 (https=)
CN (1) CN102947330B (https=)
AU (1) AU2011217027B2 (https=)
CA (1) CA2789492C (https=)
CY (1) CY1117697T1 (https=)
DK (1) DK2536746T3 (https=)
ES (1) ES2572388T3 (https=)
GB (1) GB201002730D0 (https=)
HR (1) HRP20160475T1 (https=)
HU (1) HUE027952T2 (https=)
PL (1) PL2536746T3 (https=)
RS (1) RS54744B1 (https=)
RU (1) RU2604813C2 (https=)
SI (1) SI2536746T1 (https=)
WO (1) WO2011101681A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
ES3011307T3 (en) 2012-02-23 2025-04-07 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
EP4592400A3 (en) 2012-10-17 2025-10-29 10x Genomics Sweden AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
JP6748061B2 (ja) * 2014-07-09 2020-08-26 ルピン・リミテッド 二重シストロン細菌発現システム
US11059880B2 (en) 2015-06-30 2021-07-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Redirected cells with MHC chimeric receptors and methods of use in immunotherapy
US12577289B2 (en) 2015-06-30 2026-03-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Surrogate co-receptors for t cells and methods of use
MX2018004875A (es) 2015-10-22 2018-08-01 Juno Therapeutics Gmbh Metodos para cultivar celulas y kits y aparatos para ello.
EP3365453A2 (en) 2015-10-22 2018-08-29 Juno Therapeutics GmbH Methods, kits, agents and apparatuses for transduction
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
US20180127481A1 (en) * 2016-11-09 2018-05-10 Uti Limited Partnership RECOMBINANT pMHC CLASS II MOLECULES
JP7339160B2 (ja) 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法
DE102018122546B3 (de) 2018-09-14 2019-12-05 Immatics Biotechnologies Gmbh Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden
EP4345453B1 (en) * 2018-09-28 2025-11-12 10X Genomics, Inc. High throughput epitope identification and t cell receptor specificity determination using loadable detection molecules
SG11202104355SA (en) 2018-10-31 2021-05-28 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP3719033A1 (en) * 2019-04-02 2020-10-07 imusyn GmbH & Co. KG Stabilized mhc i
WO2021035049A1 (en) * 2019-08-21 2021-02-25 Uti Limited Partnership Improved recombinant pmhc molecules
EP4028412A2 (en) * 2019-09-13 2022-07-20 The Regents of The University of California Systems and methods for the preparation of peptide-mhc-i complexes with native glycan modifications
US20220409732A1 (en) * 2019-12-02 2022-12-29 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
DE102020109447A1 (de) 2020-04-03 2021-10-07 Jacobs University Bremen Ggmbh Synthetisches mhc-klasse-ii-protein
US12534510B2 (en) 2020-04-16 2026-01-27 The Regents Of The University Of California Peptide-receptive MHC-I complex compositions and methods
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN118813436A (zh) * 2023-07-24 2024-10-22 佳吾益(北京)科技有限公司 展示单mhc等位基因功能蛋白的工程化细胞
CN119220425A (zh) * 2023-07-28 2024-12-31 佳吾益(北京)科技有限公司 发现mhc新抗原肽表位的工程化细胞
WO2025137580A1 (en) * 2023-12-22 2025-06-26 Antiger Therapeutics, Inc. Class ii hla with inter-chain disulfide bond

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006749A2 (en) * 1996-08-16 1998-02-19 President And Fellows Of Harvard College Soluble monovalent and multivalent mhc class ii fusion proteins, and uses therefor
WO2006102170A2 (en) * 2005-03-18 2006-09-28 Oregon Health & Science University Recombinant mhc molecules useful for manipulation of antigen-specific t cells
RU2303264C2 (ru) * 2001-02-19 2007-07-20 Мерк Патент Гмбх Способ идентификации эпитопов т-клеток и его применение для получения молекул со сниженной иммуногенностью

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010457A1 (en) 1989-03-14 1990-09-20 New York University Method of treating hiv infections using immunotoxins
CA2302779C (en) * 1997-09-16 2010-02-02 Oregon Health Sciences University Recombinant mhc molecules useful for manipulation of antigen-specific t-cells
WO1999060120A2 (en) * 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
US8377447B2 (en) * 2003-09-05 2013-02-19 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
ES2709176T3 (es) 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
JP5154564B2 (ja) * 2006-12-01 2013-02-27 カール・ツァイス・エスエムティー・ゲーエムベーハー 像収差を低減するための交換可能で操作可能な補正構成を有する光学システム
ES2445152T3 (es) 2007-08-20 2014-02-28 Nextera As Presentación en fagos de pVII

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006749A2 (en) * 1996-08-16 1998-02-19 President And Fellows Of Harvard College Soluble monovalent and multivalent mhc class ii fusion proteins, and uses therefor
RU2303264C2 (ru) * 2001-02-19 2007-07-20 Мерк Патент Гмбх Способ идентификации эпитопов т-клеток и его применение для получения молекул со сниженной иммуногенностью
WO2006102170A2 (en) * 2005-03-18 2006-09-28 Oregon Health & Science University Recombinant mhc molecules useful for manipulation of antigen-specific t cells

Also Published As

Publication number Publication date
KR20130009782A (ko) 2013-01-23
GB201002730D0 (en) 2010-04-07
WO2011101681A2 (en) 2011-08-25
JP5537675B2 (ja) 2014-07-02
AU2011217027B2 (en) 2015-02-05
CA2789492C (en) 2017-04-18
ES2572388T3 (es) 2016-05-31
KR101647176B1 (ko) 2016-08-09
US8828379B2 (en) 2014-09-09
PL2536746T3 (pl) 2016-08-31
RS54744B1 (sr) 2016-10-31
SI2536746T1 (sl) 2016-09-30
RU2012138302A (ru) 2014-03-27
WO2011101681A3 (en) 2011-12-08
US20130171668A1 (en) 2013-07-04
US9056920B2 (en) 2015-06-16
JP2013519721A (ja) 2013-05-30
HUE027952T2 (en) 2016-11-28
EP2536746A2 (en) 2012-12-26
US20140349315A1 (en) 2014-11-27
HRP20160475T1 (hr) 2016-06-03
CN102947330B (zh) 2015-09-16
CY1117697T1 (el) 2017-05-17
CA2789492A1 (en) 2011-08-25
AU2011217027A1 (en) 2012-09-06
EP2536746B1 (en) 2016-04-20
CN102947330A (zh) 2013-02-27
DK2536746T3 (en) 2016-05-30

Similar Documents

Publication Publication Date Title
RU2604813C2 (ru) Функциональные растворимые гетеродимеры мнс ii класса со стабилизирующей дисульфидной связью
KR102415259B1 (ko) 조작된 고-친화도의 인간 t 세포 수용체
KR102250696B1 (ko) Ｔ 세포 수용체 조작
EP1882700B1 (en) Biotinylated MHC complexes and their uses
Landais et al. New design of MHC class II tetramers to accommodate fundamental principles of antigen presentation
AU3945999A (en) Soluble t cell receptor
Justesen et al. Functional recombinant MHC class II molecules and high-throughput peptide-binding assays
US20240262885A1 (en) Systems and methods for the preparation of peptide-mhc-i complexes with native glycan modifications
US20230059548A1 (en) Systems and methods for identification of mhc-i peptide epitopes
US20240076356A1 (en) Display of peptide-mhc (pmhc) on multimeric protein scaffolds and uses thereof
Moro et al. Generation of functional HLA-DR* 1101 tetramers receptive for loading with pathogen or tumour derived synthetic peptides
Yang et al. Expression of HLA-DP0401 molecules for identification of DP0401 restricted antigen specific T cells
Fortin et al. MMTV superantigens coerce an unconventional topology between the TCR and MHC class II
HK1177939B (en) Disulphide bond-stabilized functional soluble mhc class ii heterodimers
Lunde et al. Stabilizing mutations increase secretion of functional soluble TCR-Ig fusion proteins
WO2016059018A1 (en) DETECTION OF IgM ANTIBODIES USING AN IMMUNE COMPLEX (IC) ELISA
Sharma et al. Refolding of HLA-B27 heavy chains in the absence of β2m yields stable high molecular weight (HMW) protein forms displaying native-like as well as non-native-like conformational features: Implications for autoimmune disease
MXPA00011367A (en) Soluble t cell receptor
MXPA00011368A (en) Multivalent t cell receptor complexes

Legal Events

Date Code Title Description
HE9A Changing address for correspondence with an applicant